Related Experiment Video
Updated: May 25, 2026
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
E. coli-produced BMP-2 as a chemopreventive strategy for colon cancer: a proof-of-concept study
Saravanan Yuvaraj1, Sa'ad H Al-Lahham, Rajesh Somasundaram
1Department of Cell Biology, University Medical Center Groningen, University of Groningen, A. Deusinglaan 1, 9713 AV Groningen, The Netherlands.
Abstract:
Colon cancer is a serious health problem, and novel preventive and therapeutical avenues are urgently called for. Delivery of proteins with anticancer activity through genetically modified bacteria provides an interesting, potentially specific, economic and effective approach here. Interestingly, bone morphogenetic protein 2 (BMP-2) is an important and powerful tumour suppressor in the colon and is thus an attractive candidate protein for delivery through genetically modified bacteria. It has not been shown, however, that BMP production in the bacterial context is effective on colon cancer cells. Here we demonstrate that transforming E. coli with a cDNA encoding an ileal-derived mature human BMP-2 induces effective apoptosis in an in vitro model system for colorectal cancer, whereas the maternal organism was not effective in this respect. Furthermore, these effects were sensitive to cotreatment with the BMP inhibitor Noggin. We propose that prevention and treatment of colorectal cancer using transgenic bacteria is feasible.
Insights
Genetically modified bacteria delivering bone morphogenetic protein 2 (BMP-2) effectively induced apoptosis in colorectal cancer cells. This novel approach shows promise for preventing and treating colon cancer.
Area of Science:
- Oncology
- Microbiology
- Biotechnology
Background:
- Colorectal cancer necessitates innovative prevention and treatment strategies.
- Genetically modified bacteria offer a potential platform for targeted protein delivery.
- Bone morphogenetic protein 2 (BMP-2) exhibits tumor-suppressive properties in the colon.
Purpose of the Study:
- To investigate the efficacy of BMP-2 delivered by genetically modified bacteria against colorectal cancer cells.
- To determine if bacterial production of BMP-2 can induce apoptosis in an in vitro colorectal cancer model.
Main Methods:
- Transformation of E. coli with cDNA encoding human BMP-2.
- In vitro testing of engineered E. coli on a colorectal cancer cell model.
- Assessment of apoptosis induction and sensitivity to BMP inhibitor Noggin.
Main Results:
- Engineered E. coli successfully induced apoptosis in colorectal cancer cells.
- The effect was specific to bacterial delivery, not observed with the maternal organism.
- Apoptosis induction was sensitive to the BMP inhibitor Noggin, confirming BMP-2's role.
Conclusions:
- Transgenic bacteria expressing BMP-2 are effective in targeting and inducing apoptosis in colorectal cancer cells.
- This bacterial delivery system presents a feasible strategy for colorectal cancer prevention and therapy.
- Further research into bacterial-mediated protein delivery holds significant therapeutic potential.
